Aria’s Symphony™ platform can, using interpretable disease-specific models, predict which drug candidates are likely to be efficacious. This allows our scientists to select and advance lead candidates that have the best likelihood of success.
We are constantly testing and improving Symphony™. One way we’ve always done that is by “rediscovering” support for successful clinical trials completed by other companies. Now we’re taking that a step further and sharing our predictions for Phase 2 candidates that have yet to report trial results.
The list below represents candidates that our Symphony™ drug discovery platform predicts will achieve efficacy in their respective Phase 2 trials. Stay tuned for additional quarterly updates.
DISEASE | DRUG | MECHANISM OF ACTION | CLINICAL TRIAL END DATE | CLINICAL TRIAL LINK | PREDICTION PUBLISHED DATE |
---|---|---|---|---|---|
Schizophrenia | Ulotaront | Trace Amine-Associated Receptor 1 & 5-hydroxytryptamine Type 1A Against | January 6, 2023 | December 23, 2022 | |
Asthma | Tozorakimab | Anti-IL33 Antibody | February 6, 2023 | December 15, 2022 | |
Psoriatic Arthritis | JNJ-77242113 | IL-23 Receptor Antagonist | February 24, 2023 | December 15, 2022 | |
Psoriasis | JNJ-77242113 | IL-23 Receptor Antagonist | February 24, 2023 | December 15, 2022 | |
Nonalcoholic Steatohepatitis (NASH) | HPG-1860 | FXR Agonist | March 2023 | December 15, 2022 | |
Amyotrophic Lateral Sclerosis (ALS) | Pridopidine | Sigma-1 Receptor Agonist & D2 Receptor Antagonist | March 2023 | December 15, 2022 | |
Idiopathic Pulmonary Fibrosis (IPF) | BMS-986263 | Serpin H1 Inhibitor | September 2022 | August 31, 2022 | |
Atopic Dermatitis | CMK-389 | Anti-IL18 Antibody | October 6, 2022 | August 31, 2022 | |
Nonalcoholic Steatohepatitis (NASH) | Efinopegdutide | GLP-1/Glucagon Receptor Dual Agonist | October 20, 2022 | August 31, 2022 | |
Type-2 Diabetes | Retatrutide | GLP-1/Glucagon Receptor/GIPR Tri-agonist | October 29, 2022 | October 25, 2022 | |
Epilepsy | Darigabat | GABAA Positive Allosteric Modulator | November 2022 | August 31, 2022 |
Aria’s drug discovery engine.
Drug discovery is complex. Our technology decodes complex biology in an unprecedented manner, combining the widest biomedical data landscapes available with proprietary, purpose-built artificial intelligence. Symphony™ is the only AI drug discovery platform that integrates and simultaneously analyzes unrelated heterogenous data in one process. We see the whole picture, increasing our chance of fully understanding the biology and detecting a signal others can’t see.
Background
Aria’s proprietary drug-discovery AI-platform, Symphony™, is at the center of the company’s prediction capabilities. Using Symphony™ and its unprecedented ability to simultaneously integrate and interrogate the widest biomedical data landscapes, Aria decodes a disease’s complex biology by building an interpretable in silico model. These disease-specific models accurately predict which drug candidates will be significantly efficacious in the disease.
Validating Symphony™ predictions with “rediscovery”
One of the prime ways Aria’s researchers verify the viability of the disease-specific models built on Symphony™ is how well those models blindly “rediscover” previously investigated treatments. That is, how well the models do at retrospectively identifying drug candidates that succeeded in clinical trials even when those outcomes are hidden from Symphony™.
The way this works is that for a given disease, Aria researchers identify all treatments that have completed Phase 2 or beyond; all those drugs are then divided into two groups: training and testing. Each group is carefully chosen to ensure no overlap between drug targets, receptors, or ligands. This careful splitting is important to avoid data leakage, and thereby ensures all retrospective analyses that follow are fully blinded.
The training group of treatments is used to finalize the disease-specific models Symphony™ produces. Aria researchers can then examine the efficacy predictions Symphony™ makes for every treatment in the testing group. Because all treatments in the testing group are unlabeled to Symphony™, this is an excellent and unbiased way to measure the quality of predictions.
Aria has recently completed this process for more than 30 disease-specific models, allowing us to complete a fully blinded retrospective analysis on more than 400 completed Phase 2 trials. The result is that more than 80 percent of the treatments Symphony™ predicted to be efficacious passed their Phase 2.